TradesZ

Is ADMA a buy? — what our data shows

⚡ TradesZ research ·Updated June 22, 2026 ·~2 min read ·Grounded in SEC data

ADMA Biologics makes specialty plasma-derived medicines — essentially therapies made from donated human blood plasma — that help people with weakened immune systems fight off infections.

What our data shows

Our data on ADMA has two sides. The encouraging part: nearly 400 big investment funds report holding it, which is a meaningful level of institutional attention for a company this size. The cautious part: we spotted a couple of things worth knowing. The company spent around $111 million buying back its own shares — that can be a sign of confidence, but it's also a big chunk of cash out the door. There's also been a leadership change recently, which is always worth keeping an eye on.

⚪ Institutional ownership (13F)
What you see
391 13F filings name ADMA.
What it means
Broad institutional presence in the stock.
How to read it
13F positions are long positions (often read as bullish) — they lag ~45 days and guarantee nothing.
→ See smart money

The takeaway

⚪Neutral

ADMA has real institutional backing, but the hefty buyback and the management shuffle mean it's worth watching how the company explains its next moves — that's your clearest signal on where things are headed.

But watch out
Single officer-change 8-K in last 180 days.
Sources → Smart-money hub

Have your own question?

Ask in plain English — our data answers. Free for retail readers.

Ask a question →

Informational research, not personalized investment advice.